Cytosorbents Corporation (CTSO) vs IN8bio, Inc. (INAB)
A side-by-side comparison of Cytosorbents Corporation and IN8bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTSO
Cytosorbents Corporation
$3.97HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
INAB
IN8bio, Inc.
$1.42HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CTSO vs INAB
growth of $100 · dividends reinvested · last 5yCTSO -97.4% (-51.8%/yr)INAB -99.5% (-65.7%/yr)CTSO compounded faster over this window
Log scale — wide-divergence pair
CTSO INAB
CTSO vs INAB: by the numbers
- •INAB is the larger company ($14M vs $12M market cap).
- •Both run net losses; INAB's is the smaller (0.00% vs -48.94% net margin).
Metrics side by side
Valuation
| Metric | CTSO | INAB |
|---|---|---|
| P/S ratio | 0.33 | N/A |
| P/B ratio | N/A | 0.74 |
Profitability
| Metric | CTSO | INAB |
|---|---|---|
| Gross margin | 71.61% | 0.00% |
| Operating margin | -33.37% | 0.00% |
| Net margin | -48.94% | 0.00% |
| ROE | N/A | -101.66% |
| ROIC | -43.31% | -91.74% |
Growth (annualized)
| Metric | CTSO | INAB |
|---|---|---|
| Revenue CAGR (5Y) | -3.17% | N/A |
| Total return CAGR (5Y) | -52.26% | -62.88% |
Frequently asked
- How have CTSO and INAB total returns compared?
- Over the past 5 years, CTSO delivered -52.26% and INAB delivered -62.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.